602
Participants
Start Date
October 19, 2021
Primary Completion Date
October 15, 2024
Study Completion Date
January 6, 2025
Pentosan Polysulfate Sodium twice weekly
Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
Placebo (Sodium Chloride Injection, 0.9%)
Placebo to match PPS
Pentosan Polysulfate Sodium Fixed Dose
Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
Pentosan Polysulfate Sodium once weekly
Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
Australian Clinical Research Network, Maroubra
Griffith University, Southport
Sportsmed, Stepney
Linear Clinical Research Limited, Nedlands
Coastal Carolina Research Center, North Charleston
Progressive Medical Research, Port Orange
University Clinical Research-Deland, DeLand
Conquest Research, Winter Park
LMG Research, Miami
Well Pharma Medical Research, Corp., Miami
Clinical Research of West Florida, Tampa
Clinical Research of West Florida- Clearwater, Clearwater
Alliance for Multispecialty Research - Knoxville, Knoxville
Northwestern University Feinberg School of Medicine, Chicago
Alliance for Multispecialty Research - Newton, Newton
Alliance for Multispecialty Research - Wichita West, Wichita
Alliance for Multispecialty Research - Wichita East, Wichita
Clinical Investigations of Texas, Plano
Tandem Clinical Research, Marrero
Clinical Trials of Texas, Inc., San Antonio
Diagnostics Research Group - Northwest San Antonio, San Antonio
Discovery Clinical Trials, San Antonio
FutureSearch Trials - Austin, Austin
Alliance for Multispecialty Research - Tempe, Tempe
Fiel Family and Sports Medicine, Tempe
Tucson Orthopaedic Institute, Tucson
Alliance for Multispecialty Research - Las Vegas, Las Vegas
Kaplan Medical Research, Las Vegas
Core Healthcare Group, Cerritos
Providence Clinical Research, North Hollywood
Prospective Research Innovations Inc., Rancho Cucamonga
Biosolutions Clinical Research Center, La Mesa
Encompass Clinical Research, Spring Valley
Lead Sponsor
Paradigm Biopharmaceuticals USA (INC)
INDUSTRY